ECSP21072161A - LINACLOTIDE DELAYED RELEASE COMPOSITIONS - Google Patents

LINACLOTIDE DELAYED RELEASE COMPOSITIONS

Info

Publication number
ECSP21072161A
ECSP21072161A ECSENADI202172161A ECDI202172161A ECSP21072161A EC SP21072161 A ECSP21072161 A EC SP21072161A EC SENADI202172161 A ECSENADI202172161 A EC SENADI202172161A EC DI202172161 A ECDI202172161 A EC DI202172161A EC SP21072161 A ECSP21072161 A EC SP21072161A
Authority
EC
Ecuador
Prior art keywords
delayed release
release compositions
linaclotide
linaclotide delayed
compositions
Prior art date
Application number
ECSENADI202172161A
Other languages
Spanish (es)
Inventor
Mark Currie
Anil Chhettry
Ritesh Sanghvi
Angelika Fretzen
Mohammad Bari
Ahmad Hashash
Matthew Miller
Mahendra Dedihiya
Andreas Grill
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52293217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21072161(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of ECSP21072161A publication Critical patent/ECSP21072161A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas de liberación retardada que comprenden linaclotida o sales farmacéuticamente aceptables de esta, así como a varios métodos y procesos para la preparación y uso de las composiciones.The present invention relates to sustained release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as various methods and processes for the preparation and use of the compositions.

ECSENADI202172161A 2013-12-11 2021-09-28 LINACLOTIDE DELAYED RELEASE COMPOSITIONS ECSP21072161A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361914951P 2013-12-11 2013-12-11
US201361914952P 2013-12-11 2013-12-11

Publications (1)

Publication Number Publication Date
ECSP21072161A true ECSP21072161A (en) 2021-11-18

Family

ID=52293217

Family Applications (2)

Application Number Title Priority Date Filing Date
ECIEPI201659106A ECSP16059106A (en) 2013-12-11 2016-07-08 LINACHLOTIDE DELAYED RELEASE COMPOSITIONS
ECSENADI202172161A ECSP21072161A (en) 2013-12-11 2021-09-28 LINACLOTIDE DELAYED RELEASE COMPOSITIONS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ECIEPI201659106A ECSP16059106A (en) 2013-12-11 2016-07-08 LINACHLOTIDE DELAYED RELEASE COMPOSITIONS

Country Status (29)

Country Link
US (7) US20160310560A1 (en)
EP (2) EP3079669B1 (en)
JP (4) JP6964380B2 (en)
KR (3) KR102509291B1 (en)
CN (3) CN112569199A (en)
AU (3) AU2014362220B2 (en)
CA (1) CA2933587C (en)
CL (1) CL2016001424A1 (en)
CY (1) CY1123953T1 (en)
DK (1) DK3079669T3 (en)
EA (1) EA201691216A1 (en)
EC (2) ECSP16059106A (en)
ES (1) ES2838007T3 (en)
HR (1) HRP20201753T1 (en)
HU (1) HUE052981T2 (en)
IL (2) IL246155A0 (en)
LT (1) LT3079669T (en)
MX (2) MX386584B (en)
NZ (2) NZ759512A (en)
PE (2) PE20211976A1 (en)
PH (1) PH12016501122B1 (en)
PL (1) PL3079669T3 (en)
PT (1) PT3079669T (en)
RS (1) RS61133B1 (en)
SG (2) SG11201604729QA (en)
SI (1) SI3079669T1 (en)
SM (1) SMT202000686T1 (en)
UA (1) UA119335C2 (en)
WO (2) WO2015089326A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119335C2 (en) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. LINACLOTID COMPOSITIONS WITH DELAYED RELEASE
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2016125064A1 (en) * 2015-02-02 2016-08-11 Aurobindo Pharma Ltd Stable compositions comprising linaclotide
JP2018516937A (en) * 2015-06-05 2018-06-28 アイアンウッド ファーマシューティカルズ インコーポレイテッド Modified or targeted release formulation of linaclotide
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
WO2017156214A1 (en) * 2016-03-11 2017-09-14 Gateway Pharmaceutical LLC Pharmaceutical compositions for colon-specific delivery
US11534404B2 (en) * 2016-10-06 2022-12-27 Sucampo Ag Multilayer beads for pharmaceutical use
CN110475564A (en) * 2016-12-21 2019-11-19 硬木药品公司 Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide
KR102227486B1 (en) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 Oral solid formulation composition comprising proton pump inhibitor, oral solid formulation comprising the same and manufacturing method thereof
EA202092275A1 (en) * 2018-03-23 2021-02-09 Палатин Текнолоджиз, Инк. COMPOSITIONS OF PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR AND METHODS OF DELIVERY TO THE GASTROINTESTINAL TRACT
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN114206324A (en) * 2019-06-10 2022-03-18 硬木药品公司 Treatment of abdominal pain associated with diarrhea predominant irritable bowel syndrome
KR102104507B1 (en) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same
CN110935007B (en) * 2019-12-12 2023-06-23 烟台大学 Linaclotide compound composition, preparation, application and preparation method thereof
GB202017863D0 (en) * 2020-11-12 2020-12-30 Intract Pharma Ltd Novel compositions
CN115105582A (en) * 2021-03-17 2022-09-27 江苏豪森药业集团有限公司 Pharmaceutical composition containing linaclotide or linaclotide salt and preparation method thereof
WO2022245650A1 (en) * 2021-05-19 2022-11-24 Alberto Paz Orally administered compositions for cancer treatment
IL319961A (en) * 2022-10-03 2025-05-01 Brim Biotechnology Inc Compositions comprising pedf-derived short peptides (pdsp) and uses thereof
TW202440065A (en) * 2022-12-28 2024-10-16 日商中外製藥股份有限公司 Solid dispersion containing a dispersed object substance, pharmaceutical composition containing the same and method for producing the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN201252259Y (en) * 2008-07-24 2009-06-03 富士康(昆山)电脑接插件有限公司 Electrical connector
RS60101B1 (en) * 2008-08-15 2020-05-29 Ironwood Pharmaceuticals Inc Linaclotide-containing formulations for oral administration
JP5964589B2 (en) * 2008-12-03 2016-08-03 シナジー ファーマシューティカルズ インコーポレイテッド Preparation of guanylate cyclase C agonist and method of use thereof
US20130012454A1 (en) * 2009-07-06 2013-01-10 Ironwood Pharmaceuticals, Inc. Orally Disintegrating Compositions of Linaclotide
WO2011019819A1 (en) * 2009-08-12 2011-02-17 Forest Laboratories Holdings Limited Orally disintegrating compositions of linaclotide
US8748573B2 (en) * 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
RU2012109415A (en) * 2009-08-13 2013-09-20 Айронвуд Фармасьютикалз, Инк. METHOD FOR MODULATION OF PHARMACODYNAMIC EFFECT OF ORAL-INJECTED GUANILATICYCLASE RECEPTOR AGONISTS
CA2790213A1 (en) * 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
ES2763404T3 (en) * 2010-08-11 2020-05-28 Ironwood Pharmaceuticals Inc Stable linaclotide formulations
US20140162963A1 (en) * 2010-09-11 2014-06-12 Forest Laboratories Holdings Limited Treatment of Constipation-Predominant Irritable Bowel Syndrome
JP2012155108A (en) * 2011-01-26 2012-08-16 Kyocera Document Solutions Inc Developing roller, developing device and image forming apparatus
CN104053449B (en) * 2011-08-17 2016-12-07 硬木药品公司 The treatment of gastrointestinal tract disease
WO2013047795A1 (en) * 2011-09-30 2013-04-04 アステラス製薬株式会社 Granular pharmaceutical composition
JP2016521249A (en) * 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド Linaclotide composition
EP2958577A2 (en) * 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
UA119335C2 (en) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. LINACLOTID COMPOSITIONS WITH DELAYED RELEASE

Also Published As

Publication number Publication date
EP3079669B1 (en) 2020-09-30
WO2015089335A1 (en) 2015-06-18
KR20210152588A (en) 2021-12-15
CN115089556A (en) 2022-09-23
KR102509291B1 (en) 2023-03-14
LT3079669T (en) 2020-12-10
EP3821881A1 (en) 2021-05-19
PT3079669T (en) 2020-11-30
US20160310559A1 (en) 2016-10-27
MX2016007625A (en) 2016-12-09
NZ721952A (en) 2022-05-27
PE20161373A1 (en) 2016-12-17
JP7483656B2 (en) 2024-05-15
RS61133B1 (en) 2020-12-31
JP6964380B2 (en) 2021-11-10
CN112569199A (en) 2021-03-30
JP2019073559A (en) 2019-05-16
SG11201604729QA (en) 2016-07-28
HUE052981T2 (en) 2021-05-28
WO2015089326A9 (en) 2016-08-04
AU2014362220A1 (en) 2016-06-30
JP2021113227A (en) 2021-08-05
PL3079669T3 (en) 2021-04-06
SI3079669T1 (en) 2021-01-29
SG10201804817TA (en) 2018-07-30
PH12016501122A1 (en) 2016-07-18
AU2020202319A1 (en) 2020-04-23
MX386584B (en) 2025-03-04
SMT202000686T1 (en) 2021-01-05
PH12016501122B1 (en) 2023-05-24
CA2933587C (en) 2023-09-26
WO2015089326A1 (en) 2015-06-18
NZ759512A (en) 2022-05-27
US20180015139A1 (en) 2018-01-18
JP2017504590A (en) 2017-02-09
UA119335C2 (en) 2019-06-10
MX2021011906A (en) 2021-10-26
PE20211976A1 (en) 2021-10-05
EP3079669A1 (en) 2016-10-19
US20220031802A1 (en) 2022-02-03
EA201691216A1 (en) 2016-11-30
US20240075094A1 (en) 2024-03-07
IL246155A0 (en) 2016-07-31
BR112016013419A2 (en) 2017-09-26
KR20160132001A (en) 2016-11-16
CY1123953T1 (en) 2022-03-24
DK3079669T3 (en) 2020-11-02
ES2838007T3 (en) 2021-07-01
AU2022201891A1 (en) 2022-04-07
US20200038476A1 (en) 2020-02-06
CN106659687A (en) 2017-05-10
US20160310560A1 (en) 2016-10-27
CA2933587A1 (en) 2015-06-18
KR20230039764A (en) 2023-03-21
US20170157200A1 (en) 2017-06-08
ECSP16059106A (en) 2017-02-24
KR102337809B1 (en) 2021-12-10
HRP20201753T1 (en) 2020-12-25
JP2023126475A (en) 2023-09-07
AU2014362220B2 (en) 2020-04-30
IL283012A (en) 2021-06-30
CL2016001424A1 (en) 2017-09-08
AU2020202319B2 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
ECSP16059106A (en) LINACHLOTIDE DELAYED RELEASE COMPOSITIONS
CL2015002335A1 (en) 2-Aminopyrimidine derivatives for the treatment of viral infections.
CL2015000295A1 (en) Compounds derived from alkylpyrimidine; pharmaceutical composition that includes them; Use for the treatment of viral infections and other diseases.
UY34651A (en) ? DOSAGE FORMS OF IMMEDIATE RELEASE OF HANDLING, PROCESSES TO PREPARE THEM, METHODS AND USES OF THE SAME? ..
MX2016010213A (en) Novel pharmaceutical formulations.
MX2015003140A (en) Formulations of enzalutamide.
BR112016000489A2 (en) compound, pharmaceutical composition comprising it, use of the composition and methods for making compounds
CL2015003801A1 (en) Antibody formulations and methods
JOP20140114B1 (en) Heterocyclic compounds and their uses
UY35661A (en) NEW PHOSPHATE DERIVATIVES, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT
MX2015012833A (en) ANTIBIOTIC COMPOSITIONS OF CEFTOLOZANO.
CL2015000408A1 (en) Compounds derived from pyrazolo [4,3-d] pyrimidine and its salts; pharmaceutical composition that includes them, useful for the treatment of allergic, inflammatory, infectious or cancer diseases.
ECSP16074478A (en) NOVEL COMPOUNDS
CR20170077A (en) OPTIONALLY CONDENSED HEREROCICLYL PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOINMUNITY DISEASES
UY35276A (en) New compounds that inhibit the activity of Lp-PLA2
CR20120549A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE HYDROMORPHONE AND NALOXONE
MX340983B (en) Pharmaceutical and nutraceutical compositions of abscisic acid.
SV2017005412A (en) COMPOUNDS OF 1-RENT-6-OXO-1,6-DIHIDROPIRIDIN-3-ILO AND USES OF THE SAME
CL2015002488A1 (en) Novel abexinostat salt, related crystalline form, method of preparation of this and the pharmaceutical compositions containing it
PE20150167A1 (en) (R) -NIFURATEL, ITS USE FOR THE TREATMENT OF INFECTIONS AND SYNTHESIS OF (R) AND (S) -NIFURATEL
MX391152B (en) PHARMACEUTICAL FORMULATIONS COMPRISING HIGH PURITY CANGRELOR AND METHODS FOR PREPARING AND USING SAME.
DOP2018000049A (en) COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS
UY34552A (en) CRYSTAL FORM DELTA OF THE ARGININE SALT OF PERINDOPRILE, ITS PREPARATION PROCEDURE, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
UA117233C2 (en) Sustained release formulations of lorazepam
GT201200066A (en) NEW DIHIDRO-OXAZOLOBENZODIAZEPINONAS DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM